Background/Aims: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL. Methods: This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen 1 -positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. Results: Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4 developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%, P=0.036). Conclusions: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL. (Korean J Hepatol 2011;17:299-306)
clearance, leading to chronic hepatitis and liver cirrhosis. 2 An immune-compromised status, such as after liver transplantation, can enhance HCV viral replication, and it is probably secondary to impairment of cellular immunity.
Likewise, data from patients infected with HCV receiving cytotoxic chemotherapy for hematological malignancies show that liver dysfunction by enhanced replication of HCV may be a possible complication, whereas it is less common and less severe than that due to hepatitis B virus (HBV) reactivation. [3] [4] [5] However, cases of severe hepatitis with hepatic decompensation from enhanced HCV replication have been reported. 5 Transarterial chemo-embolization (TACE) has become the most common non-surgical management for unresectable HCC. Because TACE increases the survival rates in patients with unresectable HCC, it is currently considered the primary therapy. [6] [7] [8] However, TACE is not indicated for those with poor hepatic reserve, as it is related to more complications and worse prognoses in those cases. Yoshikawa et al achieved. However, this procedure can also lead to worsening of liver function, although the frequency was relatively low. 9 TACL was reported to possibly reactivate HBV replication in HBsAg-positive HCC patients irrespective of baseline viral status. 10 According to that study, performed at our institution, HBV reactivation during TACL resulted in hepatitis, hepatic decompensation, and even death. 10 However, no detailed study has examined enhanced HCV replication in HCC patients during TACL. In this retrospective study, the frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. 
PATIENTS AND METHODS

Patients
Laboratory tests
Seropositivity for anti-HCV antibody was determined using third-generation enzyme immunoassays (Abbott Laboratories, North Chicago, IL, USA). Baseline HCV RNA titers were checked before commencement of treatment, and follow-up titers were checked before each course of treatment using real-time polymerase chain reaction (Biosewoom, Inc.
Seoul, Korea). All patients were followed up at intervals of less than 2 months. At baseline, HCV genotype was determined by the VERSANT HCV genotype assay (LiPA 2.9, Belgium). Immunology, Tokyo, Japan) using monoclonal antibodies to the preS2 region, as previously described. 11 All patients
were followed up at intervals of less than 2 months in a similar manner to those with positive anti-HCV antibodies.
TACL-related ischemic injury of the liver can also elevate liver enzymes, but it did not seem to last more than two weeks. 10 We checked the liver enzymes at least 1 month after prior TACL to discern hepatitis due to enhanced viral replication from ischemic injury.
Definitions
Enhanced We defined HBV reactivation as reappearance or an increase of over 10 fold in serum HBV DNA compared with the baseline level, as mentioned in previous reports. 12, 13 Hepatitis attributed to HBV reactivation and hepatic decompensation during TACL were defined in the same manner as enhanced HCV replication. 
Treatment methods
Statistical analyses
Analyses were conducted using the independent-sample t-test, Mann-Whitney U-test, chi-square test, or Fisher's exact test, as appropriate. Two-tailed P-values <0.05 were considered significant. Significant variables from the univariate analysis were then included in a multivariate analysis using a logistic regression model to identify the independent predictors of each phenomenon. Data were analyzed using SPSS software (SPSS 15.0; SPSS, Inc., Chicago, IL, USA).
Ethics statement
The study was approved by the Ethics Committee of the Catholic University of Korea (KC11RISI0508). All subjects provided signed informed consent to participate in this research study. HCV, hepatitis C virus; HBV, hepatitis B virus; ALT, alanine aminotransferase; AFP, α-fetoprotein; Epi, epirubicin; Cis, cisplatin; Doxo, doxorubicin.
RESULTS
Study population
were HBeAg-positive. For 13 patients, HBV DNA was below 2000 copies/mL, and they were all HBeAg negative. HBV genotyping performed in 46 patients showed that all were genotype C (100%).
The age of diagnosis and tumor size was significantly different between these two groups. The patients in the HBV seropositive group were younger, and their tumor size was larger. Eleven out of thirteen patients with enhanced HCV Table 3 . The elevation of ALT was mild, except in Total number of cycles 3.6±0. (Table 3) .
Enhancement of HCV replication and occurrence of hepatitis compared with HBV reactivation
Factors associated with enhanced HCV replication
To evaluate the clinical factors related to the enhancement of HCV replication during TACL, 10 variables were compared in patients with and without enhanced HCV replication during TACL (Table 4) . No statistically significant factors were found, including baseline HCV RNA copies or HCV genotypes.
DISCUSSION
The reactivation of hepatitis virus during systemic chemotherapy for malignancies is a significant problem that can lead to hepatic failure. 15 The mechanism of viral reactivation is unclear but may involve a two-stage process, as described by Xunrong et al. 16 The first or initial stage is This process has been emphasized more frequently in HBV infection than in HCV, and preemptive antiviral therapy against HBV has been proven to be efficacious to prevent hepatitis attributed to viral reactivation during systemic chemotherapy and TACE. [17] [18] [19] [20] [21] [22] TACL has been shown to reactivate HBV infection in previous reports, and its immunosuppressive effect on chemotherapeutic agents infused during TACL was the suggested mechanism. 10, 19 HCV replication was also enhanced during TACL, and no statistically significant difference in the frequency of viral reactivation between HBV and HCV was observed in this study. However, no relevant clinical factors that contributed to HCV reactivation during TACL were identified. Previous studies reported that genotype 2c
carriers are at high risk of hepatitis reactivation in an untreated cohort of patients with chronic HCV infection. 23 There was also a case series suggesting that HCV genotype 2 might be a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 24 But we were unable to identify an association between enhanced replication of HCV and viral genotype.
Interestingly, two patients with initially undetectable HCV RNA titers later developed enhanced viral replication.
Anti-HCV positive patients without HCV RNA for more than 6 months are considered to be cured of hepatitis C.
These patients have cleared the virus either spontaneously or due to treatment. Of our two patients, one had no history of treatment, and the other had undergone interferon therapy. It is generally believed that hepatitis C virus is not completely eliminated from the body but is under control of the immune system. HCV RNA has been reported to be present in the liver and peripheral blood mononuclear cells of patients with no detectable serum HCV RNA. 25, 26 The possible cause for enhanced replication of HCV during TACL can be suggested, considering the attenuated activity of cellular immune response in liver by TACL.
Previous studies showed that HCV viremia recurred in a patient and in a chimpanzee after serum samples consistently tested negative for HCV RNA using a nested reversetranscription PCR method for 4 months after normalization of ALT levels. 27, 28 In both cases, loss of HCV specific CD4+
T-cell responses preceded HCV recurrence. Additionally, in vivo depletion of CD8+ T cells resulted in prolonged viremia, which was controlled only when HCV-specific CD8+ T cells reappeared in the liver. 29 Taken together, these studies indicate that the adaptive cellular immune system, whose important components are CD4+ and CD8+ T cells, is crucial in controlling HCV replication, and attenuated activity of the cellular immune response can result in enhanced HCV replication in the liver.
Our study showed that the hepatitis and/or hepatic decompensation attributed to enhanced replication of HCV during TACL was significantly less frequent than that of HBV. This phenomenon may be the result of different immunogenic characteristics between these two viruses. A recent study described that human HCV-specific T cells differ in their effector functions from human HBV-specific T cells. Whereas HBV-specific CD8+ T cells express high levels of perforin and show vigorous proliferation, IFN-γ production, and cytotoxic activity on in vitro stimulation, 30 these effector functions are reduced in HCV-specific T cells. [30] [31] [32] The different degree of cytotoxicity between HBV-specific and HCV-specific CD8+ cells may contribute to a different pattern of viral reactivation and of hepatitis due to reactivation.
Additionally, HCV has escape mechanisms that contribute to the high chronicity rate of the viral infection and the attenuated course of new infections. These escape mechanisms might also prevent serious immune-mediated hepatic damage after enhanced viral replication during TACL. One important escape mechanism is viral-sequence mutations, 33 and several other mechanisms might also contribute to the observed impairment of HCV-specific immune responses.
In conclusion, TACL can enhance replication of HCV, but the possibility of hepatitis and hepatic decompensation attributed to enhanced HCV replication would be lower than that of HBV reactivation in patients undergoing TACL. This discrepancy may result from differences in immunogenicity between HBV and HCV. Further prospective studies with large numbers of patients are required to confirm this suggestion.
Concomitantly, the necessity of preemptive and/or targeted antiviral therapy for enhanced HCV replication during TACL should be evaluated.
